> top > docs > PMC:7402624 > spans > 40598-40862 > annotations

PMC:7402624 / 40598-40862 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T373 37-40 Body_part denotes HLA http://purl.org/sig/ont/fma/fma84795
T374 51-56 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T375 233-236 Body_part denotes HLA http://purl.org/sig/ont/fma/fma84795
T376 247-252 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
1430 32-36 Gene denotes CD38 Gene:952
1431 45-48 Gene denotes CD8 Gene:925
1432 228-232 Gene denotes CD38 Gene:952
1433 241-244 Gene denotes CD8 Gene:925
1437 4-12 Species denotes patients Tax:9606
1438 193-201 Species denotes patients Tax:9606
1447 134-146 Chemical denotes nitric oxide MESH:D009569

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T680 32-36 http://purl.obolibrary.org/obo/PR_000001408 denotes CD38
T681 45-48 http://purl.obolibrary.org/obo/CLO_0053438 denotes CD8
T682 49-56 http://purl.obolibrary.org/obo/CL_0000084 denotes T cells
T683 228-232 http://purl.obolibrary.org/obo/PR_000001408 denotes CD38
T684 241-244 http://purl.obolibrary.org/obo/CLO_0053438 denotes CD8
T685 245-252 http://purl.obolibrary.org/obo/CL_0000084 denotes T cells

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T282 41-43 Chemical denotes DR http://purl.obolibrary.org/obo/CHEBI_73445
T283 134-146 Chemical denotes nitric oxide http://purl.obolibrary.org/obo/CHEBI_16480
T284 141-146 Chemical denotes oxide http://purl.obolibrary.org/obo/CHEBI_25741|http://purl.obolibrary.org/obo/CHEBI_29356
T286 237-239 Chemical denotes DR http://purl.obolibrary.org/obo/CHEBI_73445

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T235 0-264 Sentence denotes All patients who had decreasing CD38+HLA-DR+ CD8 T cells from day 0 to day 7 were treated with early vasoactive medication or inhaled nitric oxide whereas these treatments were less common for patients with stable or increasing CD38+HLA-DR+ CD8 T cells (fig. S6E).